Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 13/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.48 |
| ▸ | STK4 | Q13043 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070809 | 0.86 | MAP3K8 (0.53) | MAP3K8EGFRERBB2STK4 | |
| SCHEMBL4963013 | 0.83 | EGFR (0.51) | MAP3K8EGFRERBB2 | |
| SCHEMBL6071202 | 0.80 | KMT2A (0.45) | MAP3K8 | |
| SCHEMBL6071770 | 0.80 | MAP3K8 (0.50) | MAP3K8EGFRERBB2STK4 | |
| SCHEMBL6071775 | 0.78 | MAP3K8 (0.61) | MAP3K8EGFRERBB2 | |
| SCHEMBL1896697 | 0.78 | EGFR (0.63) | MAP3K8EGFRERBB2STK4 | |
| SCHEMBL6384817 | 0.77 | EGFR (0.54) | MAP3K8EGFRERBB2STK4 | |
| SCHEMBL6071744 | 0.76 | MAP3K8 (0.55) | MAP3K8EGFRERBB2 | |
| SCHEMBL6071434 | 0.74 | MAP3K8 (0.69) | MAP3K8EGFRERBB2 | |
| SCHEMBL1895110 | 0.73 | EGFR (0.53) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | MAP3K8 84/4885EGFR 4122/4885ERBB2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.